Intriguingly, no differences in the alleviation of dermatitis-like symptoms in the AD mouse model, including dermatitis scores, ear thickness, scratching frequency, TEWL (Figure S5A,B), and the expression of claudin-1 (Figure S5C), were observed between mice treated with AMP-IBP5 via topical application and those treated via injection. Here, CLDN1 is linked to dermatitis.